Anti-VRK2 antibody,Abcam,AB184875

Target data Serine/threonine kinase that regulates several signal transduction pathways (PubMed : 14645249, PubMed : 16495336, PubMed : 16704422, PubMed : 17709393, PubMed : 18286207, PubMed : 18617507, PubMed : 20679487). Isoform 1 modulates the stress response to hypoxia and cytokines, such as interleukin-1 beta (IL1B) and this is dependent on its interaction with MAPK8IP1, which assembles mitogen-activated protein kinase (MAPK) complexes (PubMed : 17709393). Inhibition of signal transmission mediated by the assembly of MAPK8IP1-MAPK complexes reduces JNK phosphorylation and JUN-dependent transcription (PubMed : 18286207). Phosphorylates 'Thr-18' of p53/TP53, histone H3, and may also phosphorylate MAPK8IP1 (PubMed : 16704422). Phosphorylates BANF1 and disrupts its ability to bind DNA and reduces its binding to LEM domain-containing proteins (PubMed : 16495336). Down-regulates the transactivation of transcription induced by ERBB2, HRAS, BRAF, and MEK1 (PubMed : 20679487). Blocks the phosphorylation of ERK in response to ERBB2 and HRAS (PubMed : 20679487). Can also phosphorylate the following substrates that are commonly used to establish in vitro kinase activity : casein, MBP and histone H2B, but it is not sure that this is physiologically relevant (PubMed : 14645249).. Isoform 2. Phosphorylates 'Thr-18' of p53/TP53, as well as histone H3. Reduces p53/TP53 ubiquitination by MDM2, promotes p53/TP53 acetylation by EP300 and thereby increases p53/TP53 stability and activity. See full target information Serine/threonine-protein kinase VRK2